Anteo Diagnostics Key People
Jack Hamilton career spans over 30 years in the energy sector. He has held senior positions across the energy sector over the past 15 years including heading up Australia’s largest resource project as Director North West Shelf Ventures for Woodside Energy Ltd., CEO for a Liquid Natural Gas project in PNG following on from a 21 year career with Shell in both local and international roles. His career gained experience across a range of functions including, strategy development, commercial marketing, mergers/acquisitions, capital raisings, manufacturing operations and project management in the energy and petrochemical sectors.
Jack is currently a non-executive director with Calix Ltd. as well as, on the advisory board for GHD Advisory, a division of GHD Engineering Ltd. He formerly held directorships with DUET Group Ltd, Southern Cross Electrical Engineering, Federation Training and chair of Renu Energy Ltd and Antilles Oil and Gas NL.
He graduated from Melbourne University with a degree in Bachelor of Chemical Engineering and a Doctorate of Philosophy in 1981 before joining Shell. Jack is married with two children and is resident in Melbourne, Victoria.
- Nomination and Remuneration Committee Member
- Audit and Risk Committee Member
- Managing Director and CEO (Jan 2009 – Jun 2016)
- Non-Executive Director (Jun 2016 – )
Dr Cumming has over 20 years experience in the healthcare and biotechnology market. Geoff’s roles have progressed from pure research to sales and marketing roles through to Managing Director level and Board seats. Previously Managing Director of Roche Diagnostic Systems – Oceania Regional Centre, where he transformed a loss making business to one achieving over 30% compound annual growth over a four year period and the highest profitability levels in Roche’s global organisation. Geoff was also Managing Director and CEO of an Australian based biotechnology company commercialising a range of products in cancer diagnosis and treatment. Dr Cumming is a Non-Executive Director of Medical Australia Limited (ASX: MLA) and Chairman of Sienna Cancer Diagnostics Limited (ASX:SDX).
- Non-Executive Director (Oct 2017 – )
Mr Sanderson joined the Anteo board as a Non-Executive Director in October 2017. He has been a director of private investment companies investing in public and private companies for the last 10 years. At Anteo, Matt’s objective is to provide focus on strategy and profitable execution and commercial growth of the technology. He is also strongly focused on providing shareholders with a clear and concise communication platform.
- Company Secretary (Aug 2017– )
Mr McInally has been a Director/CFO/Company Secretary and has over 16 years experience with publicly listed companies on the TSX, AIM, and ASX stock exchanges in the resources and agriculture related industries. He has expertise in capital raisings, mergers and acquisitions, project and asset evaluation, strategy, commercial agreements, statutory and management reporting and compliance and governance obligations of publicly listed companies.